公开(公告)号：US11905284B2

公开(公告)日：2024-02-20

申请号：US17335666

申请日：2021-06-01

申请人： PFIZER INC.

发明人： Lei Zhang ,  Christopher Ryan Butler ,  Elizabeth Mary Beck ,  Michael Aaron Brodney ,  Matthew Frank Brown ,  Laura Ann McAllister ,  Erik Alphie LaChapelle ,  Adam Matthew Gilbert

IPC分类号： C07D471/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61K31/437

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28

摘要： The present invention provides, in part, compounds of Formula I:




or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

公开(公告)号：US11339159B2

公开(公告)日：2022-05-24

申请号：US16926933

申请日：2020-07-13

申请人： Pfizer Inc.

发明人： Omar Ahmad ,  Andrew Fensome ,  Erik Alphie LaChapelle ,  Ethan Lawrence Fisher ,  Rayomand J. Unwalla ,  Jun Xiao ,  Lei Zhang

IPC分类号： C07D471/04 ,  A61K31/437

摘要： The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US10028962B2

公开(公告)日：2018-07-24

申请号：US15629215

申请日：2017-06-21

申请人： Pfizer Inc.

发明人： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill ,  Gabriela Barreiro ,  Erik Alphie LaChapelle ,  Bruce Nelsen Rogers

IPC分类号： C07D519/00 ,  C07D513/04 ,  A61K31/542

CPC分类号： C07D513/04 ,  A61K31/542 ,  C07D519/00

摘要： The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US09744173B2

公开(公告)日：2017-08-29

申请号：US15427350

申请日：2017-02-08

申请人： Pfizer Inc.

发明人： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill ,  Gabriela Barreiro ,  Erik Alphie LaChapelle ,  Bruce Nelsen Rogers

IPC分类号： C07D519/00 ,  C07D513/04 ,  A61K31/542

CPC分类号： A61K31/542 ,  C07D513/04 ,  C07D519/00

摘要： The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20170145022A1

公开(公告)日：2017-05-25

申请号：US15426423

申请日：2017-02-07

申请人： Pfizer Inc.

发明人： Thomas Allen Chappie ,  Nandini Chaturbhai Patel ,  Matthew Merrill Hayward ,  Christopher John Helal ,  Simone Sciabola ,  Erik Alphie LaChapelle ,  Joseph Michael Young ,  Patrick Robert Verhoest

IPC分类号： C07D487/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D519/00

摘要： The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

公开(公告)号：US20170008911A1

公开(公告)日：2017-01-12

申请号：US15215193

申请日：2016-07-20

申请人： Pfizer Inc.

发明人： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill ,  Gabriela Barreiro ,  Erik Alphie LaChapelle ,  Bruce Nelsen Rogers

IPC分类号： C07D513/04 ,  C07D519/00

CPC分类号： A61K31/542 ,  C07D513/04 ,  C07D519/00

摘要： The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

摘要翻译： 并且变量R1如说明书中所定义。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

公开(公告)号：US20160039828A1

公开(公告)日：2016-02-11

申请号：US14817606

申请日：2015-08-04

申请人： Pfizer Inc.

发明人： Thomas Allen Chappie ,  Patrick Robert Verhoest ,  Nandini Chaturbhai Patel ,  Matthew Merrill Hayward ,  Christopher John Helal ,  Simone Sciabola ,  Erik Alphie LaChapelle ,  Joseph Michael Young

IPC分类号： C07D487/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D519/00

摘要： The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，其中取代基R 1，R 3，R 6，R 7和b如本文所定义。 本发明还涉及包含化合物的药物组合物，使用该化合物的治疗方法，以及制备化合物的方法。

公开(公告)号：US11976064B2

公开(公告)日：2024-05-07

申请号：US17738074

申请日：2022-05-06

申请人： Pfizer Inc.

发明人： Omar Ahmad ,  Andrew Fensome ,  Erik Alphie LaChapelle ,  Ethan Lawrence Fisher ,  Rayomand J. Unwalla ,  Jun Xiao ,  Lei Zhang

IPC分类号： A61K31/4745 ,  A61K31/437 ,  C07D471/04

CPC分类号： C07D471/04 ,  A61K31/437

摘要： The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US20230192690A1

公开(公告)日：2023-06-22

申请号：US18112156

申请日：2023-02-21

申请人： PFIZER INC.

发明人： Lei Zhang ,  Christopher Ryan Butler ,  Elizabeth Mary Beck ,  Michael Aaron Brodney ,  Matthew Frank Brown ,  Laura Ann McAllister ,  Erik Alphie LaChapelle ,  Adam Matthew Gilbert

IPC分类号： C07D471/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61K31/437

CPC分类号： C07D471/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61K31/437

摘要： The present invention provides, in part, compounds of Formula I:




or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

公开(公告)号：US11472805B2

公开(公告)日：2022-10-18

申请号：US15736942

申请日：2016-06-09

申请人： Pfizer Inc.

发明人： Thomas Allen Chappie ,  Nandini Chaturbhai Patel ,  Patrick Robert Verhoest ,  Christopher John Helal ,  Simone Sciabola ,  Erik Alphie LaChapelle ,  Travis T. Wager ,  Ramalakshmi Yegna Chandrasekaran

IPC分类号： C07D471/14 ,  C07D491/147 ,  C07D491/22 ,  C07D513/14 ,  C07D519/00 ,  C07D487/04 ,  C07D487/14 ,  C07D498/22 ,  C07D471/22

摘要： The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.